REPORT HIGHLIGHTS
-
The U.S. in vitro toxicity (predictive toxicity) testing market has been valued at $765 million in 2006. At a compound annual growth rate (CAGR) of 14.4%, the total U.S. market will grow to reach $1.5 billion by 2011.
-
Mechanistic toxicology testing had the highest growth through the forecast period, with an estimated CAGR of 21.8%. This sector of the market will be worth $720 million by 2011.
-
Non-mechanistic toxicology testing was the larger of the two sectors in 2006. Even with a CAGR of 9.4%, it will still maintain the majority of the market at $780 million in 2011.
REPORT SCOPE
INTRODUCTION
BCC's goal in conducting this study was to determine the current status of the U.S. in vitro toxicity testing market and assess its growth potential over the 5-year period from 2006 to 2011. We were particularly interested in understanding the current market scenario for alternative measures to animal testing. Predictive toxicology is often cross-referenced with in vitro methods. This report assesses the growth and market potential for these methods. In addition, we were interested in understanding the impact of these methods on different industry sectors.
Our key objective was to present a comprehensive analysis of the current in vitro toxicity testing market in the United States and its future direction.
SCOPE OF STUDY
This report contains:
- An overview of the in-vitro toxicology testing market, explaining basic principles and practices, definitions, classes of tests, and the different types of toxicology
- A technical overview that describes toxicology testing strategies, the various toxicology categories, and alternatives to the standard toxicology methods
- An in-depth review of the current market status, historical market data, compound annual growth rates, and forecasts to 2011
- Information on specific technology in the markets, including revenues and developments
- A thorough analysis of patents and profiles of the major players.
METHODOLOGY
BCC presents an analysis by the different technology approaches and revenue split by different applications for 2006. Then, based on our surveys, we analyze the potential of the technologies that encompass mechanistic and non-mechanistic and forecast revenue projections for 2006 and 2011. We also analyze revenues by the four major industry groups that use toxicology testing.
INFORMATION SOURCES
BCC surveyed numerous companies to obtain data for this study. Included were manufacturers of reagents and test kits for different toxicity testing categories, contract research organizations, testing services for toxicity, and some technology vendors. We also spoke with end users in different industries. In addition, we compiled data from government sources.
ABOUT THE AUTHOR
Vanita Khetan is a healthcare domain analyst and an entrepreneur. She holds a bachelors degree in Chemistry and a postgraduate degree in Management. During the course of her career, she has analyzed U.S., European and Asian markets in biotechnology, pharmaceuticals, medical devices, wound care, and surgical goods. This is her first publication with BCC Research.
